XPhyto Therapeutics Commences Trading on the CSE
(firmenpresse) - Vancouver, Canada (August 6, 2019) - XPhyto Therapeutics Corp. (CSE:XPHY) (XPhyto or the Company) is pleased to announce that its common shares will commence trading today on the Canadian Securities Exchange (the "CSE") under the ticker symbol XPHY.
Trading on the CSE is a significant corporate milestone on our way to becoming a major player in the next wave of cannabis investment opportunities, said Hugh Rogers, CEO of XPhyto. With XPhytos recently announced German cannabis cultivation and extraction licence and its certified R&D processing and formulation capability coming online in Canada, the XPhyto team is strongly positioned to execute on its corporate strategy over the coming year.
About XPhyto Therapeutics Corp.
XPhyto is a science-based cannabis company focused on formulation, clinical validation, and emerging European markets. XPhytos 100% owned German subsidiary, Bunker Pflanzenextrakte GmbH, has been granted a unique German cannabis cultivation and extraction licence for scientific purposes by the German Federal Institute for Drugs and Medical Devices (BfArM). XPhyto is pursuing additional opportunities in Germany including cultivation, processing, manufacturing, import, and distribution. In Canada, two exclusive 5-year engagements with the Faculty of Pharmacy at a major Canadian university provide certified extraction, isolation, and formulation facilities, drug research and development expertise, as well as commercial analytical testing capability.
For further information, please contact:
Hugh Rogers
CEO & Director
+1.780.818.6422
info(at)xphyto.com
www.xphyto.com
Robert Barth
VP European Corporate Development
+49 8331 99481 10
info(at)xphyto.com
www.xphyto.com
Forward looking statements
This news release includes statements containing forward-looking information within the meaning of applicable Canadian securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as develop, "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "potential", "propose" and other similar words, or statements that certain events or conditions "may" or "will" occur, and in this release include the statement regarding the Company''s goal of building an industry leading medical cannabis company Forward-looking statements are only predictions based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements, including: that the Company may not derive the expected, or any, benefits from the Licence; that the Company may be unable to scale its business; product liability risks; frequent changes to cannabis regulations in Canada and internationally; general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; competition; international risks; and other risks beyond the Company''s control. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this news release.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
XPhyto ist ein wissenschaftlich ausgerichtetes Cannabisunternehmen, das analytische Test-, Verarbeitungs- und Formulierungskapazitäten in Kanada entwickelt, während sich das Unternehmen in Deutschland auf Forschung, Anbau, Extraktion, Import, Vertrieb und Herstellung konzentriert.
" alt="FE Limited: Significant Prospectivity identified at Hillside Project">
" alt="Sovereign Metals: Further Rutile Testwork Confirms Attractive Product Sizing">
Datum: 06.08.2019 - 08:43 Uhr
Sprache: Deutsch
News-ID 1551235
Anzahl Zeichen: 3029
contact information:
Contact person:
Town:
Wien
Phone:
Kategorie:
Business News
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 422 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"XPhyto Therapeutics Commences Trading on the CSE
"
steht unter der journalistisch-redaktionellen Verantwortung von
XPhyto Therapeutics Corp. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
